Trade Ideas November 19, 2026 10:12 AM

Buying Coherent Ahead of the $20B AI Deal Rerate - Positioning for Early 2028 Upside

A conviction long: margin expansion + booked demand should re-rate COHR well before the formal ramp.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
COHR

<p>Coherent just booked a $20 billion long-term agreement with a hyperscaler and reported Q1 FY27 results showing 50% revenue growth and a major margin improvement. The share price has retraced from its $440 peak but remains richly valued on trailing EPS. I think the market underestimates how quickly margins and bookings can be priced in once visible capacity and early shipments accelerate. This is a buy for a long-term trade (180 trading days) with defined risk controls.</p>

Buying Coherent Ahead of the $20B AI Deal Rerate - Positioning for Early 2028 Upside
COHR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Coherent booked a $20B long-term AI data center agreement and reported Q1 FY27 with 50% revenue growth and significant margin expansion.
  • Management raised long-term gross margin targets above 45% by 2028; Q1 non-GAAP gross margin was 40.6% and operating margin 23.2%.
  • Market cap ~ $44.2B, trailing P/E ~44x, EV/EBITDA ~24.9x; stock is priced for growth but not full margin durability.
  • Trade plan: buy at $225.67, stop $190.00, target $350.00, horizon long term (180 trading days).

Hook / Thesis
Coherent (COHR) just landed a $20 billion long-term agreement with a leading AI data center customer and posted a blowout Q1 FY27 quarter on 11/13/2026 that showed 50% revenue growth and sizable margin expansion. The company has already guided to higher long-term gross margins and is investing heavily to meet demand. I view this as a classic visibility-to-profitability re-rating: once capacity utilization and early shipments make the $20B cadence believable, the multiple should expand into the mid- to high-teens EV/EBITDA regime. That creates a compelling asymmetric trade now.

Why the market should care
Coherent is positioned at the intersection of lasers, compound semiconductors and optical interconnects - the core hardware stack for hyperscale AI connectivity. The $20B deal brings a multi-year, high-margin revenue stream that, if executed, materially changes the company's scale and margin profile. In Q1 FY27 management reported a non-GAAP gross margin of 40.6% (up 184 bps) and operating margin of 23.2%, with non-GAAP EPS of $2.09 (an 80% year-over-year jump). Those are the kinds of operating leverage numbers that drive multiple expansion.

The business in a paragraph
Coherent develops and manufactures engineered materials, opto-electronic components and lasers across three segments: Networking, Materials, and Lasers. Customers include data center hyperscalers (for optical connectivity), semiconductor capital equipment (for lasers), and industrial and instrumentation end markets. The Networking segment leverages compound semiconductor technology and system-level integration; that is where the $20B agreement sits and where the fastest growth and highest incremental margins are coming from.

Hard numbers that support the bullish case

  • Recent quarter (reported 11/13/2026): revenue grew ~50% to $2.37B and non-GAAP EPS was $2.09.
  • Profitability: non-GAAP gross margin expanded to 40.6% and operating margin to 23.2% in the quarter.
  • Valuation snapshot: market cap ~ $44.2B with a trailing P/E near 44x and price-to-sales ~5.3x; enterprise value ~ $44.37B and EV/EBITDA ~ 24.9x.
  • Balance sheet and cash flow: shares outstanding ~196.96M, free cash flow most recently reported as negative $1.83B (reflecting heavy capex to scale), and management flagged capex of ~$776M to meet booked demand through 2027.

Put simply: management is investing heavily to convert a large booked opportunity into recurring high-margin revenue. The margin gains in Q1 and the raised long-term gross margin targets (management now targets above 45% by 2028) are the critical proof points that will determine whether market sentiment flips from growth-at-all-costs to growth-with-margin expansion.

Valuation framing
At a market cap roughly $44B and trailing P/S of ~5.3x, the stock is already priced for strong growth. That said, the current multiple embeds little upside for additional margin expansion beyond the 40%+ level. If Coherent reaches gross margins north of 45% and sustains operating margins in the low-to-mid 20s as management projects, investors should be willing to pay a higher multiple given the recurring nature of hyperscaler contracts and the scale benefits in Networking. The company currently trades at EV/EBITDA ~25x despite negative recent free cash flow - a reflection of high expected growth. If the $20B contract starts to produce visible revenue and cash flow in the coming quarters, a sensible re-rating target would be toward a 15-18x forward EV/EBITDA multiple as execution risk falls; that would imply meaningful upside from current levels even assuming conservative margins.

Technical / positioning context
The stock retraced from a 52-week high of $440 to a 52-week low of $130 last year and has stabilized around the low $200s. Today the price is roughly $225.67, near the 10–20 day moving average range (SMA10 ~$217, SMA20 ~$214) and comfortably below the 50-day SMA (~$247). Momentum indicators are neutral-to-mildly bullish (RSI ~49; MACD showing bullish histogram). Short interest is notable but days-to-cover is low (around 1-1.7 days historically), which suggests shorts can be squeezed quickly if positive catalysts accelerate.

Catalysts to watch (2-5)

  • Capacity ramp updates and shipment timing from management - concrete dates and volumes will be the first sign that the $20B deal is de-risking.
  • Quarterly margin progression - sequential gross margin improvement toward the mid-40s is the clearest proof of operating leverage.
  • PhotonLink / Networking revenue cadence - management expects PhotonLink-related revenues to rise (PhotonLink was highlighted as a growth vector with $250M projected by end-2027); earlier-than-expected revenue recognition is a catalyst.
  • Order backlog disclosures and capex cadence - evidence that booked demand is converting to firm orders and yield improvements will shift valuation assumptions.

Trade plan (actionable)
I am initiating a long position in COHR here with the following parameters:

Entry Stop Target Direction Horizon
$225.67 $190.00 $350.00 Long Long term (180 trading days)

Rationale: entry at $225.67 captures a pullback into moving-average support and lets us buy into visible margin improvement without paying for the full psychological premium near the year-to-date highs. The stop at $190 cuts exposure below the near-term technical support band and limits downside if demand disappoints or execution slips. The $350 target assumes a re-rating alongside sustained margin gains and visible order conversion; it sits well below the 52-week high of $440 and reflects a multiple expansion toward a more justified EV/EBITDA for a scaled networking franchise.

Horizon explanation: I choose long term (180 trading days) because meaningful progress on capacity, shipments and margin expansion should be visible well before early 2028. In my view, the market will start to price in the $20B stream as bookings convert into firm, shippable orders and as capex translates into capacity and yield improvements.

Risk profile and downside scenarios
Investors must respect both execution and market risks. Key risks include:

  • Execution risk: Scaling production to meet hyperscaler timelines is non-trivial. The company flagged ~$776M of capex to hit booked demand through 2027; delays, yield problems, or cost overruns would compress margins and push out revenue recognition.
  • Concentration / customer risk: A large portion of the upside comes from a single long-term agreement. Any renegotiation, delay, or change in customer strategy could materially change the thesis.
  • Cash flow and leverage risk: Recent free cash flow was negative $1.83B, reflecting heavy investment. If capex continues to outpace cash generation, the company may need to access capital markets at unattractive terms, weighing on the equity.
  • Valuation risk: The company trades at a premium multiple (P/E ~44x) relative to normalized industrial peers, so the stock is sensitive to any slowdown in growth or margin progression.
  • Competitive risk: Optical and compound semiconductor markets are competitive and attract supply-chain entrants; new competitors or faster scale by peers could undercut pricing or share.

Counterargument to my thesis
A reasonable bear case is that the $20B deal is heavily back-ended, conditional, or subject to stringent performance milestones that will not be met on the timetable the market desires. If management's capex fails to deliver yield improvements, margins could compress instead of expand, leaving the company with expensive fixed assets and slower-than-expected revenue conversion. That outcome would likely keep multiples compressed and push the stock materially lower.

What would change my mind
I will reassess this position if any of the following occur:

  • Management reports repeated misses on shipment timing or yields tied to the contract.
  • Quarterly gross margins trend downward or stall materially below the 40% level.
  • Free cash flow continues to deteriorate without a clear path to breakeven despite the ramp (i.e., capex grows faster than revenue conversion).
If, conversely, we see clear, sequential revenue recognition against the $20B agreement and margins move toward the mid-40s, I would add to the position.

Bottom line
Coherent offers an asymmetric look: a very large customer agreement and early evidence of margin leverage versus capital-intensive execution risk. At $225.67 the market is giving the company the benefit of growth but not the full benefit of margin durability. If you believe management can execute the capacity build and convert bookings into repeatable revenue, the stock has meaningful upside toward my $350 target over the next 180 trading days. Trade size should be sized to tolerate execution volatility and the non-trivial capex path; use the $190 stop to keep the risk-reward reasonable.

Entry: $225.67 | Stop: $190.00 | Target: $350.00 | Horizon: Long term (180 trading days)

Risks

  • Execution risk: capex scale-up (~$776M) could face delays or yield issues, delaying revenue and compressing margins.
  • Customer concentration: the upside depends on large customer demand; any change in the customer's roadmap or allocation could reduce expected revenue.
  • Cash flow and funding risk: negative free cash flow (-$1.83B) amid heavy capex could force dilutive financing if cash conversion lags.
  • Valuation sensitivity: current multiples (P/E ~44x, EV/EBITDA ~24.9x) leave little margin for error if growth or margins slow.

More from Trade Ideas

Backing PRAX into a Busy FDA Window - Initiate a Speculative Buy Nov 19, 2026 Why UnitedHealth's Dip on Medicare Fraud Headlines Looks Like a Buying Opportunity, Not a Showstopper Nov 19, 2026 HNGE Upgrade: Profitability Expansion Turns Hinge Health Into a Tactical Buy Nov 19, 2026 Golar LNG: FLNG #4 Is the Narrative Spark — Buy the Re-rating Around Contract Wins Nov 19, 2026 Buy Broadcom Now: Practical Idea to Ride AI Upside While the Market Sleeps Nov 19, 2026